What Is 7-Hydroxymitragynine? Kratom’s Most Potent Alkaloid, Explained

7-hydroxymitragynine — usually shortened to 7-HMG or 7-OH — is a minor alkaloid found in trace or undetectable amounts in dried kratom leaf. It forms mainly through oxidation of mitragynine after harvest, rather than being something the living plant produces in significant quantity. Despite its scarcity in the leaf, it’s one of the most pharmacologically active compounds associated with kratom in laboratory testing.

The widely repeated claim that 7-HMG is “46 times more potent than mitragynine” comes from in vitro intestinal-tissue experiments; potency multipliers measured in living animals are considerably smaller. Research published in 2019 showed that the body actually manufactures some 7-HMG on its own, by metabolizing mitragynine after ingestion — meaning 7-HMG isn’t just a plant compound, it’s also something your liver makes. That distinction matters, because isolated and concentrated 7-HMG products sold today are chemically and pharmacologically a different animal from whole-leaf kratom powder.

In authentic whole-leaf kratom, 7-HMG typically ranges from undetectable to about 0.05% by weight, with most commercial US products clustering around a median of 0.01%. One liquid extract tested as high as 0.21% (Sharma et al., 2025, n=341). Researchers generally treat 1% of the total alkaloid content as the threshold above which adulteration becomes likely; Florida’s HB 179 sets its legal limit at a 2% ratio of 7-HMG to mitragynine. Products labeled “kratom” that exceed these levels by a wide margin have been documented as semi-synthetic spike-ups rather than concentrated leaf material.

What Is 7-Hydroxymitragynine?

7-hydroxymitragynine is an indole alkaloid found in Mitragyna speciosa, the kratom tree. Japanese researchers at Chiba University first isolated and characterized it in the 1990s while studying the plant’s chemistry. Structurally, it’s mitragynine with one extra hydroxyl group attached at position 7 of the indole ring.

That single addition changes the pharmacology considerably. Mitragynine behaves as what researchers call an atypical opioid — a partial agonist at mu- and delta-opioid receptors that recruits relatively little beta-arrestin-2, a signaling pattern linked to lower respiratory depression risk compared with classical opioids. 7-HMG, by contrast, binds much more tightly to the mu-opioid receptor and produces stronger downstream activity. Matsumoto and colleagues showed in 2004 that 7-HMG produced strong pain-relieving effects in mice on both the tail-flick and hot-plate tests, and that naloxone blocked those effects — confirming the opioid receptor as the mechanism. Follow-up experiments with selective blocking agents pinned the mu-opioid receptor as the main site of action.

Because it grips opioid receptors so much more tightly than mitragynine does, 7-HMG has become a focal point in both pharmacology research and regulatory debate. Understanding what it actually is — and isn’t — matters for anyone trying to make sense of kratom products on the market.

How Much 7-HMG Is Actually in Kratom Leaf?

This is the question that matters most in practice, and the answer surprises a lot of people: in properly dried, well-handled kratom leaf and powder, standard HPLC or UPLC lab testing usually can’t detect 7-HMG at all, or finds it only at trace levels below 0.05% by weight.

A 2009 study by Kikura-Hanajiri and colleagues, using HPLC and UPLC-MS across multiple kratom samples, found mitragynine consistently dominant at 1.2–2.4% in whole-leaf material (with concentrated resins running higher), while 7-HMG showed up only at trace concentrations, often near or below what the testing method of the time could reliably detect. Detection limits vary by method, and results below that threshold are properly reported as “Not Detected” rather than zero.

Testing across a broad set of commercial kratom powders shows a similar pattern: mitragynine typically reads between 1.1% and 1.8%, while 7-HMG consistently comes back as not detected or below 0.1 mg/g — well under the roughly 0.05% ceiling seen across the market. That’s the expected chemical signature of authentic, unaltered kratom leaf.

Alkaloid	Typical % Dry Weight	Typical mg/g	Primary Receptor Target(s)
Mitragynine	1.0–3.0%	10–30 mg/g	MOR partial agonist, adrenergic, serotonergic
7-Hydroxymitragynine	<0.05% (often ND)	<0.5 mg/g (often ND)	MOR partial agonist (higher efficacy than mitragynine)
Speciociliatine	~0.4–0.8%	4–8 mg/g	MOR partial agonist
Paynantheine	~0.2–0.6%	2–6 mg/g	5-HT₁A/5-HT₂B serotonin receptors; weak antagonist at mu-/kappa-opioid receptors
Corynantheidine	<0.1%	<1 mg/g	MOR partial antagonist
Speciogynine	~0.2–0.5%	2–5 mg/g	5-HT₁A/5-HT₂B serotonin receptors; opioid-independent antinociception

In practical terms, a 2-gram serving of quality kratom powder delivers roughly 24–30 mg of mitragynine and less than 0.2 mg of 7-HMG — often none at all. That ratio, along with the total alkaloid mix, shapes kratom’s overall pharmacology.

Buyer’s takeaway: When a certificate of analysis (COA) lists 7-HMG as “ND” or under 0.1 mg/g, that’s what genuine, unaltered whole-leaf powder should look like. If that line is missing entirely, or reads above roughly 0.5 mg/g for leaf powder, the product likely isn’t what the label suggests. Ask for the batch-specific COA before buying, and look specifically for that line.

Is 7-HMG Actually a Natural Plant Alkaloid?

This question sounds academic, but it has real consequences. Some sellers of 7-OH products argue that because trace 7-HMG shows up in dried kratom leaf, isolated 7-HMG products count as a “kratom-derived alkaloid” — and are therefore botanically and legally equivalent to kratom itself. The chemistry doesn’t really support that leap.

Mitragynine, kratom’s most abundant alkaloid, reacts readily with oxygen. Oxidation at the C7 position slowly converts mitragynine into 7-HMG during drying, storage, and exposure to light over time — which explains why fresh leaf shows essentially no 7-HMG, while aged, dried powder picks up trace amounts. The plant itself isn’t manufacturing 7-HMG through its own biosynthesis; the oxidation happens after harvest.

There’s a second pathway, described in more detail below: your liver oxidizes mitragynine into 7-HMG after you swallow it. A third pathway — used by manufacturers of isolated 7-OH products — is deliberate industrial-scale chemical oxidation of concentrated mitragynine starting material. All three routes produce the identical molecule, but the resulting concentrations differ enormously. Post-harvest oxidation in dried leaf keeps 7-HMG below roughly 0.05% by weight. In-body metabolism via CYP3A enzymes can push 7-HMG to somewhere between 15% and 25% of mitragynine’s plasma level after repeated dosing — meaningful, but bounded. Industrial chemical oxidation, by contrast, yields material at 70% purity or higher — more than a thousand times the concentration found in natural leaf.

None of these three pathways involves the plant synthesizing 7-HMG directly on any meaningful scale — even the slow post-harvest oxidation is really an artifact of processing, not plant chemistry.

The practical upshot: claims that isolated 7-HMG is “naturally occurring” because trace amounts turn up in dried leaf misread the underlying chemistry. Those trace amounts exist because mitragynine oxidizes easily, not because kratom plants are producing meaningful quantities of 7-HMG on their own. What a consumer swallows in an isolated 7-HMG product is a chemically converted compound, even if the starting material happened to come from a kratom plant.

Buyer’s takeaway: If a 7-HMG product markets itself as “all-natural” or “just kratom,” the chemistry doesn’t back that up. Kratom leaf doesn’t produce meaningful 7-HMG on its own — oxidation of mitragynine does, whether that happens on a drying rack, inside your liver, or in a manufacturing vessel. The first two occur through ordinary processing and normal consumption. The third is what fills bottles labeled “7-OH.”

How Does 7-HMG Compare to Mitragynine in Potency?

In a 2006 follow-up study, Matsumoto and colleagues calculated potency ratios from subcutaneous dosing in mice: 7-HMG turned out roughly 5.7 times more potent than morphine on the tail-flick test (a measure of spinal pain response) and 4.4 times more potent on the hot-plate test (a measure of pain processing higher in the nervous system). The often-quoted figures of 13 times morphine and 46 times mitragynine come from a different kind of experiment — in vitro guinea pig ileum tissue tests measuring suppression of electrically triggered muscle contractions, reported across three related studies (Takayama 2002; Matsumoto 2004; Horie 2005). Those tests found 7-HMG roughly 11 to 17 times more potent than morphine and 29 to 46 times more potent than mitragynine. That’s a different measurement — smooth-muscle response, not living-animal pain relief — and it doesn’t translate directly to how the compound behaves in a whole organism, let alone in humans.

None of this means 7-HMG is “13 times more dangerous than morphine” in any clinical sense — potency measured in rodent tissue doesn’t scale linearly to human pharmacology or risk. But it does establish that 7-HMG isn’t some harmless trace alkaloid. At elevated doses, it warrants serious pharmacological scrutiny.

Endpoint / Assay	Route	7-HMG vs Morphine	7-HMG vs Mitragynine	Source
Twitch suppression (guinea pig ileum, in vitro)	n/a	11–17× (range across 3 studies)	29–46× (range across 3 studies)	Takayama 2002; Matsumoto 2004; Horie 2005
Tail-flick antinociception (mice)	subcutaneous	5.7×	—	Matsumoto 2006
Hot-plate antinociception (mice)	subcutaneous	4.4×	—	Matsumoto 2006
Hot-plate antinociception (mice)	oral	more potent (no calculated ratio)	~3.3×	Matsumoto 2004; Berthold 2022
Respiratory depression (mice)	oral	~2×	~2.9×	Hill 2022

In whole-leaf kratom, the near-total absence of 7-HMG means its high potency is only relevant as a byproduct of mitragynine metabolism. That equation changes entirely once 7-HMG is isolated or chemically concentrated and consumed directly.

Buyer’s takeaway: A figure like “46 times more potent than mitragynine” sounds alarming, and on its own terms it is. But in whole-leaf kratom powder, 7-HMG is so scarce — often literally absent — that its higher potency barely enters into the actual experience. The number matters once you’re looking at an isolated product delivering 10–25 mg of highly enriched 7-HMG (typically 70–80% purity, with the remainder made up of unidentified oxidation byproducts) per dose. That’s not a kratom experience — it’s a different compound at a different concentration entirely.

Does Mitragynine Convert to 7-HMG in the Body?

Yes — and this discovery, published in 2019 in ACS Central Science by Kruegel and colleagues, reshaped how researchers think about kratom’s pharmacology. The study found that mitragynine undergoes oxidation in the liver, driven by cytochrome P450 3A enzymes, producing 7-hydroxymitragynine as an active metabolite.

That means when you take whole-leaf kratom powder, your body generates some 7-HMG as it processes mitragynine. Using mouse and human liver tissue in vitro, along with live-animal work in mice, the Kruegel team showed this conversion happens reliably in mammals and carries real pharmacological weight. They went further, arguing — based on measured brain concentrations of 7-HMG after mitragynine dosing — that most or all of mitragynine’s opioid-receptor-driven pain relief might actually trace back to the 7-HMG it produces as a metabolite.

Kamble and colleagues (2019) mapped out the specific enzymes involved, identifying CYP3A4 as the primary driver of mitragynine metabolism, with smaller contributions from CYP2D6 and CYP2C9. Later work by Tanna and colleagues (2021) characterized how mitragynine and 7-HMG themselves inhibit common metabolic enzymes. The key point: 7-HMG isn’t just an occasional trace contaminant in the leaf — it’s also part of what happens pharmacologically after you swallow kratom.

That said, the amount of 7-HMG your body generates from oral mitragynine appears much smaller than what isolated 7-HMG products deliver directly. Berthold and colleagues (2022) found that oral mitragynine dosing in mice produced roughly six-fold lower 7-HMG plasma exposure than direct oral dosing of 7-HMG itself at comparable amounts. It’s worth stressing this isn’t a like-for-like comparison — taking 30 mg of mitragynine doesn’t equal taking 6 mg of isolated 7-HMG, even accounting for metabolite conversion ratios of 15–25%. Human bioavailability of isolated 7-HMG hasn’t been formally studied, but the metabolic pathway from mitragynine clearly doesn’t reach the receptor-level concentrations that direct 7-HMG ingestion produces.

In humans, a 2024 study by Mongar and colleagues found that co-administering a CYP3A4 inhibitor (itraconazole, 200 mg daily for four days) alongside kratom tea cut 7-HMG plasma exposure roughly in half — confirming that CYP3A4 drives this conversion in living people. Preclinical work in rats found a more tangled picture, with CYP3A inhibition actually raising exposure to both mitragynine and 7-HMG, since the same enzyme also clears both compounds from the body (Kamble et al., 2023).

Later work by Berthold and colleagues (2022), using oral dosing and hot-plate testing — both closer to how people actually use kratom — found that 7-HMG exposure from oral mitragynine wasn’t enough on its own to account for the pain relief Kruegel’s team had attributed to it. The disagreement likely comes down to methodology: subcutaneous versus oral dosing, and different types of pain tests, rather than a real contradiction in the underlying biology. The practical conclusion: metabolic conversion of mitragynine into 7-HMG is real and biologically meaningful, but it doesn’t come close to the exposure levels produced by directly consuming isolated 7-HMG products.

This also raises drug-interaction questions. CYP3A4 inhibitors — grapefruit, certain medications — could theoretically reduce how much 7-HMG some people’s bodies generate from a given kratom dose.

Pharmacokinetic data from Trakulsrichai and colleagues (2015) showed that mitragynine reaches peak blood levels in humans around one hour after ingestion, with a terminal half-life near 23 hours. As a metabolite, 7-HMG would follow its own separate curve — peaking after mitragynine and clearing more quickly. That timing matters clinically, since it affects when receptor-level effects from the metabolite are strongest.

Buyer’s takeaway: Since the liver converts mitragynine to 7-HMG using CYP3A4 — the same enzyme grapefruit famously inhibits — anything that slows that enzyme could change how much 7-HMG your body makes from a given kratom dose. That’s not a reason to panic over occasional grapefruit juice, but it’s worth caution when combining kratom with medications known to interact with CYP3A4, such as certain antifungals or antibiotics. Anyone on prescription medication should discuss kratom use with their prescribing physician.

What Are Isolated 7-HMG Products, and How Are They Made?

Because there simply isn’t enough 7-HMG in whole kratom leaf to concentrate through ordinary extraction, commercial “7-OH” products are made through chemical synthesis or semi-synthesis. The typical route: oxidizing a highly concentrated alkaloid extract — a chemical transformation, not a botanical one.

In practice, manufacturers take a concentrated alkaloid fraction isolated from kratom leaf and react it with an oxidizing agent, such as potassium permanganate or peracetic acid, to convert mitragynine into 7-HMG. The resulting material is then purified and formulated into a finished product. This is laboratory chemistry, not a traditional plant preparation.

The finished products — usually liquid shots, gummies, or capsules marketed as “7-OH shots” or “7-hydroxymitragynine isolate” — deliver milligram-scale doses of highly enriched 7-HMG, typically 70–80% purity, with the remainder made up of unidentified oxidation byproducts. Compare that to the well under 0.2 mg of 7-HMG in a typical 2-gram serving of kratom powder. The pharmacological gap isn’t subtle.

7-OH Tablets and the 2023–2025 Surge

Since late 2023, pressed tablets have become the fastest-growing category of isolated 7-HMG products, sold in smoke shops, gas stations, convenience stores, and online. Single tablets commonly contain 5–30 mg of 7-HMG, often packaged in multi-packs meant for repeat dosing. Alongside tablets, concentrated 7-HMG also shows up in gummies, drink mixes, and shot bottles — the same categories the FDA cited in its July 2025 enforcement actions, described below. Researchers have increasingly begun treating these products as their own category rather than folding them into “kratom.”

Alsbrook and colleagues (2025) documented a rapid rise in concentrated and semi-synthetic 7-OH products marketed as “kratom” but pharmacologically and toxicologically distinct from actual kratom leaf, noting that candy-style marketing raises particular concerns about accidental exposure in children. Brown and colleagues (2026) tested commercial samples and found 7-HMG levels far outside the range seen in authentic whole-leaf material — consistent with synthetic addition rather than plant origin — and noted these products lacked the other alkaloids normally found in kratom, along with unidentified chemical peaks not present in genuine leaf. That combination points to added, unknown compounds that increase the risk profile of these products.

This shift from leaf products to isolated tablets, shots, and gummies is the main driver behind the wave of state legislation and federal enforcement now underway.

Mislabeling adds another layer of risk: some vendors sell “kratom extract” without disclosing 7-HMG concentration at all. Without a COA that reports 7-HMG specifically, there’s no way to know what’s actually in the product.

What Is 7-HMG Adulteration in Commercial Kratom?

A 2016 study by Lydecker and colleagues in Drug Testing and Analysis tested 28 commercially available kratom products and found several with 7-HMG concentrations inconsistent with authentic whole-leaf origin. The authors concluded these products had likely been spiked with synthetic 7-HMG — a practice that lets vendors produce a stronger-feeling product from cheaper, lower-alkaloid starting material.

The picture has only gotten sharper since. Brown and colleagues (2026), writing in the Journal of AOAC International, retested commercial samples marketed as kratom and again found elevated 7-HMG levels far outside the natural range — consistent with spiking or the use of chemically concentrated starting material rather than plain botanical powder. Alsbrook and colleagues (2025), in Pharmaceutical Biology, frame this as a genuine category shift — from kratom as a traditional botanical to a distinct class of 7-HMG-enriched products whose risk profile doesn’t match the evidence base built around whole-leaf use. That distinction is now driving much of the state-level policy work: the isolated or heavily concentrated compound isn’t the same product as the leaf powder it’s often sold beside.

Adulteration matters for several practical reasons:

• Consumers have no way to know actual 7-HMG content without HPLC testing
• Effects from adulterated products can differ dramatically from what buyers expect from whole-leaf kratom
• Batch-to-batch inconsistency makes dosing unpredictable
• Regulatory crackdowns triggered by adulterated products end up affecting the whole industry, including sellers of genuine leaf products

This is why a COA that explicitly reports 7-HMG — not just mitragynine — matters so much. Testing that shows ND or trace 7-HMG alongside normal mitragynine levels is meaningful evidence a product hasn’t been spiked.

Product Type	Expected 7-HMG on COA	Red Flag Result
Whole leaf powder (quality)	ND or <0.1 mg/g	>0.5 mg/g suggests adulteration
Kratom extract powder	Proportional to mitragynine enrichment; no more than 1% of total alkaloid content	7-HMG disproportionately high vs. mitragynine
Isolated 7-HMG product	7-HMG listed as primary compound, mg/dose disclosed	No 7-HMG disclosure at all
No COA available	—	Cannot assess; avoid

Buyer’s takeaway: The COA is your safety net. A legitimate report for whole-leaf powder shows mitragynine (roughly 1.2–1.8%) and 7-HMG (ND or under 0.1 mg/g) as separate entries, tested by a named ISO-accredited lab, on the specific batch you’re buying. If a vendor only reports mitragynine — or can’t provide a batch-specific report — you genuinely don’t know what’s in the package. That gap is exactly where spiking slips through undetected.

For reference: authentic whole-leaf 7-HMG runs from ND to about 0.05% by weight (0.5 mg/g); commercial powders cluster near 0.01% (Sharma 2025); anything above 0.5 mg/g deserves scrutiny; and levels above 1% of total alkaloid content point strongly toward adulteration.

What Does Research Show About 7-HMG and Abuse Liability?

The most thorough preclinical comparison to date comes from Hemby and colleagues (2018) in Addiction Biology, which tested both mitragynine and 7-HMG using rat intravenous self-administration — a standard method for gauging abuse potential.

Key findings:

• 7-HMG, unlike mitragynine, substituted for morphine in the self-administration model and was self-administered on its own in a dose-dependent way
• Mitragynine did not substitute for morphine and showed no reinforcing effects in this model
• Prior exposure to 7-HMG increased later morphine intake; prior exposure to mitragynine decreased it
• 7-HMG self-administration dropped when animals received either a mu1-selective antagonist (naloxonazine) or a delta-selective antagonist (naltrindole), implicating both receptor types in its reinforcing effects
• The authors concluded mitragynine shows no meaningful abuse potential and may even reduce opioid intake, while 7-HMG carries high abuse potential and may increase intake of other opioids

Both sides of the kratom debate tend to cite these findings selectively. The fuller picture: 7-HMG behaves like a classic opioid with real abuse potential and dose-dependent respiratory depression, while mitragynine acts as an atypical opioid partial agonist with low abuse potential and a ceiling on respiratory depression. The balance between the two compounds in whole-leaf kratom is therefore pharmacologically significant.

Hemby’s group followed up in 2026 with a paper in Frontiers in Pharmacology that expanded the receptor profiling to lesser-known kratom alkaloids — epiallo-isopaynantheine, isopaynantheine, mitraciliatine, isospeciofoline, and speciophylline — tested against human mu-, kappa-, and delta-opioid receptors. Several showed distinctive signaling behavior, including strong bias toward particular signaling pathways, and speciophylline appeared to modulate the mu-opioid receptor without binding it directly. This connects to the 7-HMG story indirectly but meaningfully: kratom’s effects can’t be reduced to just mitragynine and 7-HMG, and isolated 7-HMG products strip away a whole background of other alkaloids whose contribution to whole-leaf effects is still being worked out.

A 2025 paper by Zuarth Gonzalez and colleagues in the Journal of Pharmacology and Experimental Therapeutics found a striking divergence between the two compounds using rat breathing measurements. 7-HMG produced significant, dose-dependent respiratory depression — roughly 4.5 times more potent than morphine at cutting minute ventilation in half — and naloxone fully reversed that effect. Mitragynine, unexpectedly, increased breathing rate through a mechanism naloxone didn’t block, meaning it wasn’t acting through the mu-opioid receptor at all. The practical implication: the respiratory risk of 7-HMG-enriched products looks qualitatively different from whole-leaf mitragynine exposure, and naloxone works as a reversal agent against the 7-HMG component specifically.

A separate mouse study using whole-body plethysmography compared morphine, mitragynine, and 7-HMG directly. Oral 7-HMG caused dose-dependent respiratory depression roughly twice as potent as morphine. Mitragynine hit a ceiling — doses above 10 mg/kg produced no additional respiratory suppression, and overall it was about 2.9 times less potent than 7-HMG at this effect.

Other research has tested whole-alkaloid preparations rather than isolated compounds. One study dosed lyophilized kratom tea at 1.0 g/kg — equivalent to roughly 36 mg of mitragynine in a 60 kg adult — and found only mild, transient respiratory depression with no evidence of conditioned place preference (a common measure of addictive potential). The same research group tested kratom alkaloid extract and purified mitragynine for opioid withdrawal symptoms and found significantly fewer withdrawal signs in both groups compared with morphine.

The practical takeaway: whole-leaf kratom powder, with 7-HMG at ND or trace levels, exposes users to a complex mixture of alkaloids. Products built around concentrated 7-HMG represent a fundamentally different risk-benefit calculation.

Buyer’s takeaway: Whole-leaf kratom and isolated 7-HMG products aren’t the same thing, and treating them as one category muddies the risk picture. Quality whole-leaf powder delivers a complex alkaloid mixture, and the abuse-liability and respiratory research on it paints a different picture than classical opioids. Isolated 7-HMG products, typically dosed at 10–25 mg, shift that picture meaningfully closer to conventional opioid pharmacology. Know which one you’re actually taking.

What Is the Regulatory Status of 7-HMG vs. Kratom Leaf?

In the US, kratom — including whole-leaf powder — isn’t federally scheduled. The DEA proposed emergency scheduling of both mitragynine and 7-HMG as Schedule I substances in 2016, but withdrew that proposal after significant public and Congressional pushback. Kratom remains in a legal gray zone federally.

7-HMG specifically has drawn state-level regulatory attention because of the isolated product market. Florida’s Kratom Consumer Protection Act (HB 179 / SB 136, 2023) targeted synthetic and concentrated 7-HMG products directly while leaving traditional whole-leaf kratom largely alone — an explicit legal distinction between the isolated compound and the whole plant.

That law caps 7-HMG at 400 parts per million (0.04% by weight) in finished products and limits the 7-HMG-to-mitragynine ratio to 2%.

Federal action picked up sharply in 2025. On July 15, the FDA sent seven warning letters to companies selling concentrated 7-OH products — described in the agency’s own wording as “tablets, gummies, drink mixes, and shots” — for illegally marketing unapproved drugs and unauthorized dietary ingredients. Two weeks later, on July 29, the FDA recommended that the DEA classify 7-hydroxymitragynine as a Schedule I controlled substance. The DEA holds final scheduling authority, and as of April 2026 that rulemaking process, which includes a public comment period, is still underway. On December 2, 2025, the FDA announced the seizure of roughly 73,000 units of 7-OH products, valued around $1 million, from three firms in Missouri. Throughout, the agency has been explicit that its enforcement targets concentrated and semi-synthetic 7-OH products — not whole-leaf kratom.

Several other states are weighing or have passed similar distinctions, and the broader trend in kratom legislation is toward regulating isolated alkaloids separately from whole-leaf botanical products — a distinction that tracks with the underlying chemistry.

How Do COAs Report 7-HMG, and What Should You Look For?

A solid COA from an ISO-accredited lab reports mitragynine and 7-hydroxymitragynine as separate line items, given either as a percentage of product weight or in mg/g.

For whole-leaf kratom powder, look for:

• Mitragynine: 1.2–2.5% (12–25 mg/g) for typical whole-leaf powder. Premium or specially grown leaf can reach around 3%. Concentrated extracts and resins may show 4–7% or more, but at that point they’re no longer whole-leaf products. Note that the frequently cited 6%-plus figure from a 2009 Kikura-Hanajiri study was measured in resin, not leaf.
• 7-HMG: ND (not detected) or under 0.1 mg/g
• 7-HMG-to-mitragynine ratio: should stay very low; ratios above roughly 1:50 in powder products deserve a closer look

For extracts, mitragynine will naturally read higher due to concentration, and 7-HMG should scale proportionally with the extraction method — not disproportionately. If a 45%-mitragynine extract shows unexpectedly elevated 7-HMG, that can indicate chemical oxidation during processing or deliberate spiking.

Always ask for the full COA, not a partial panel or a summary sheet. A vendor unable to produce a batch-specific HPLC report showing 7-HMG separately from mitragynine has a real transparency gap.

Why Some Sellers Avoid Isolated 7-HMG Products

Isolated 7-HMG products were among the fastest-growing categories in the kratom-adjacent market between 2022 and 2024. Some sellers of traditional whole-leaf kratom have chosen not to carry them, and the reasoning tends to track the science rather than marketing pressure:

• Pharmacological mismatch with whole-leaf kratom. A typical 10–25 mg dose of isolated 7-HMG delivers roughly 50 to 125 times the amount of 7-HMG found in a 2-gram serving of whole-leaf powder. That’s not a stronger version of kratom — it’s a different product entirely.
• Loss of counterbalancing alkaloids. Whole-leaf kratom contains corynantheidine (a partial mu-opioid antagonist), speciociliatine, paynantheine, and dozens of other compounds that may modulate the effects of the more abundant alkaloids. Isolating 7-HMG removes that entire supporting cast.
• Shifting regulatory ground. State-level restrictions on isolated 7-HMG are tightening quickly, making it a risky category for sellers to invest in long-term.
• Quality standards. Vendors operating under frameworks like the American Kratom Association’s GMP program emphasize transparency and consumer safety — values that sit awkwardly alongside a product with this potency profile and limited human safety data.

None of this means whole-leaf kratom carries zero risk, or that 7-HMG will never have a legitimate medical use down the road. It’s a matter of proportion: the concentrations found in isolated products bear no resemblance to kratom’s traditional use pattern, and the safety science on concentrated 7-HMG in humans simply doesn’t exist yet.

Closing Thoughts

The gap between whole-leaf kratom and isolated 7-HMG products comes down to concentration and chemistry, not marketing labels. Genuine kratom leaf contains 7-HMG at trace or undetectable levels, produced mostly through oxidation rather than plant biosynthesis, and the body generates a modest, bounded amount more during normal metabolism. Isolated 7-OH products, made through deliberate chemical conversion, deliver doses far outside anything the plant or the body naturally produces. A COA that reports both mitragynine and 7-HMG separately, from an accredited lab, remains the clearest way to tell which kind of product you’re actually holding.